Develops antibiotics for the treatment of bacterial infections, focusing on novel approaches to combat resistance.
Acurx Pharmaceuticals, Inc. is an innovative clinical-stage biopharmaceutical company based in Staten Island, New York, specializing in the development of antibiotics to combat bacterial infections. At the forefront of its research is ibezapolstat, the company's lead antibiotic candidate with a unique mechanism of action targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase IIa clinical trials, demonstrating promising potential for treating patients afflicted with clostridium difficile infections.
In addition to ibezapolstat, Acurx Pharmaceuticals is advancing ACX-375C, a dual-purpose treatment designed to be administered orally or via injection. ACX-375C targets gram-positive bacteria, including challenging strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumonia. This broad-spectrum approach underscores Acurx Pharmaceuticals' commitment to addressing critical medical needs and combating antibiotic-resistant pathogens.
Founded in 2017, Acurx Pharmaceuticals leverages cutting-edge research and development strategies to innovate in the field of infectious disease therapeutics. The company's robust pipeline and scientific expertise position it as a pivotal player in the global fight against antibiotic-resistant infections, aiming to deliver effective treatments that enhance patient outcomes and contribute to public health worldwide.